Creative Biolabs Gets Ready to Fight Against SARS-CoV-2

New York, USA – With rich experience accumulated in the wars against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), Creative Biolabs is capable of handling drug discovery projects regarding the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on a global scale, which are supported by a group of Ph.D. level scientists and sophisticated technologies.

A novel type of coronavirus in December 2019 in Wuhan, China has raised growing concerns on a global scale by causing pneumonia. It shares similar symptoms with those of SARS, and hence it was named of SARS-CoV-2 (formerly known as 2019-nCoV) by the International Committee on Taxonomy of Viruses (ICTV). Since its outbreak, the fight against this 7th coronavirus that has been proved to infect humans kicked off, with pharmaceutical companies and medical researchers working wholeheartedly to find the fastest way of early diagnosis and to explore effective drugs and vaccines. Creative Biolabs has the competence to assist with relevant research projects with high-end technology platforms and years of extensive experience concentrating on drug/vaccine design & development. Solutions portfolio includes but are unlimited to SARS-CoV-2 antiviral drug discovery, SARS-CoV-2 vaccine discovery, preclinical research, in vitro diagnostic (IVD) immunoassays, of which the former 3 are drug development associated and the last applies to diagnosis of the virus, covering the 2 pressing matters at the moment.

To accelerate the drug development process, Creative Biolabs has integrated resources and research results to help exploit effective SARS-CoV-2 drug. The entire pipeline is as systematic and efficient as it can be, accompanied by state-of-the-art technologies at each step, which mainly involves neutralizing antibody development (hybridoma techniques and phage display technology), inhibitors discovery (High-Throughput Screening, HTS) and development of anti-inflammatory drugs (bioinformatics, NMR spectroscopy, computer graphics, etc.).

Specialized in immunology and having achieved dozens of successful cases in vaccine development as well, the Coronavirus Disease 2019 (COVID-19) R&D team have confidence in assisting with manufacturing safe & effective vaccines of various categories targeting the SARS-CoV-2, which consist of in silico vaccine, live attenuated and killed vaccine, recombinant subunit vaccine, mRNA vaccine and so on, covering every stage, such as the primary research, antigen development, testing for attenuation, antibody & antigen detection, and stability testing.

Comprehensive products targeting SARS-CoV-2, SARS-CoV, MERS-CoV, and other coronaviruses are also accessible.

“The virus is spreading around the world. We must control it at the fastest speed,” said a leader scientist at Creative Biolabs, “drugs and vaccines are the most common ways, and we are working on it.” The sever and emergent outbreak of SARS-CoV-2 infection spurs urgent needs for antiviral drugs and vaccines. Creative Biolabs is always paying attention to the latest news and providing helpful solutions at the best price in industry.

More relevant information can be reached at

About Creative Biolabs

Established in 2004, Creative Biolabs has been serving high-quality products and problem solutions for the researchers in the field of biology and medicine. Over a decade of innovation and development, it has grown into a prestigious CRO in the industry. While providing researchers with various products such as recombinant proteins, antibodies, and test kits, extensive research and practice experience has been accumulated in drug discovery and vaccine development, especially in the field of antiviral drugs and vaccines. Their drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services rank top worldwide.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Country: United States